You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,734,790


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,734,790
Title:Anti-TLR4 antibodies and methods of use thereof
Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
Inventor(s): Kosco-Vilbois; Marie (Minzier, FR), De Graaf; Katrien L. (Nyon, CH), Berney; Thierry (Arenthon, FR), Giovannoni; Laurianne Santa (Annemasse, FR), Bosco; Domenic (Geneva, CH)
Assignee: Novimmune SA (Geneva, CH)
Application Number:13/346,911
Patent Claims:1. A method of prolonging survival of transplanted biological material in a subject, the method comprising: (i) contacting the biological material to be transplanted with an antibody or immunologically active fragment thereof that specifically binds a Toll-like receptor 4 (TLR4) polypeptide to produce a transplantable composition; (ii) implanting the transplantable composition at a desired location in the subject; and (iii) administering to the subject one or more additional doses of an antibody or immunologically active fragment thereof that specifically binds TLR4, wherein the antibody is administered in an amount sufficient to prolong survival of the transplanted biological material in the subject, wherein the antibody or immunologically active fragment thereof that binds TLR4 in step (i), the antibody or immunologically active fragment thereof that binds TLR4 in step (iii) or the antibody or immunologically active fragment thereof that binds TLR4 in step (i) and in step (iii) comprises the heavy chain amino acid sequence MGWSWIFLFLLSGTAGVHCQVQLQESGPG LVKPSDTLSLTCAVSGYSITGGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITI SRDTSKNQFSLKLSSVTAVDTAVYYCARKDPSDAFPYWGQGTLVTVSSASTKGPSVFPL APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSSKAFPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 9) and the light chain amino acid sequence MEWSWVFLFFLSVTTGVHSEIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPD QSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGHSFPLTFGGGT KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 10).

2. The method of claim 1, wherein the subject is a human.

3. The method of claim 1, wherein the biological material to be transplanted is one or more cells or cell types, one or more tissues or tissue types, or an organ or portion thereof.

4. The method of claim 1, wherein the biological material to be transplanted is allogeneic biological material.

5. The method of claim 1, wherein the biological material to be transplanted is islet cells.

6. The method of claim 5, wherein the islet cells are allogeneic islet cells.

7. The method of claim 1, wherein the biological material to be transplanted is or is derived from kidney, pancreas, liver, or intestine.

8. The method of claim 1, where the antibody or immunologically active fragment thereof that specifically binds TLR4 in steps (i) and (iii) are the same antibody or immunologically active fragment.

9. The method of claim 1, where the antibody or immunologically active fragment thereof that specifically binds TLR4 in step (i) and the antibody or immunologically active fragment thereof that specifically binds TLR4 in step (iii) are different antibodies or immunologically active fragments.

10. The method of claim 1, wherein the antibody or immunologically active fragment thereof that binds TLR4 is a full-length fully human monoclonal antibody, a F.sub.ab fragment, a F.sub.ab' fragment or a F.sub.(ab')2 fragment, or an scFv fragment.

11. The method of claim 1, wherein the antibody or immunologically active fragment thereof that specifically binds TLR4 is administered in step (iii) in combination with one or more additional agents.

12. The method of claim 11, wherein the one or more additional agents is one or more immunosuppressive agents.

13. The method of claim 11, wherein the one or more additional agents is selected from methotrexate, cyclosporin A, tacrolimus, sirolimus, everolimus, a corticosteroid, anti-thymocyte globulin, Infliximab, Etanercept and Adalimumab.

Details for Patent 8,734,790

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2031-01-10
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2031-01-10
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2031-01-10
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2031-01-10
Immunex Corporation ENBREL etanercept Injection 103795 02/01/2007 ⤷  Try a Trial 2031-01-10
Immunex Corporation ENBREL MINI etanercept Injection 103795 09/14/2017 ⤷  Try a Trial 2031-01-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.